Royalty Pharma EVP reports 6,168-share exempt acquisition; 658,510 indirect

Rhea-AI Filing Summary

Royalty Pharma (RPRX) executive Christopher Hite reported an exempt acquisition of 6,168 Class A Ordinary Shares at $0 on 11/05/2025, in connection with the settlement of Equity Performance Awards pursuant to Rule 16b-3.

Following the reported transaction, Hite beneficially owns 658,510 shares indirectly through SCH Investment Partners LLC and 70,000 shares directly.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Hite Christopher

Role EVP & Vice Chairman

Type	Security	Shares	Price	Value
Grant/Award	Class A Ordinary Shares	6,168	$0.00	--
holding	Class A Ordinary Shares	--	--	--

Holdings After Transaction: Class A Ordinary Shares — 658,510 shares (Indirect, By SCH Investment Partners LLC); Class A Ordinary Shares — 70,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hite Christopher

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 E. 59TH STREET

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Vice Chairman

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	11/05/2025		A		6,168(1)	A	$0	658,510	I	By SCH Investment Partners LLC
Class A Ordinary Shares								70,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

Remarks:

	/s/ Sean Weisberg, as Attorney-in-Fact for Christopher Hite	11/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Royalty Pharma (RPRX) report on Form 4?

Christopher Hite reported an exempt acquisition of 6,168 Class A shares at $0 on 11/05/2025, tied to Equity Performance Awards under Rule 16b-3.

Who is the reporting person for RPRX in this filing?

It is Christopher Hite, EVP & Vice Chairman of Royalty Pharma.

How many RPRX shares does the insider own after the transaction?

Beneficial ownership stands at 658,510 shares indirectly via SCH Investment Partners LLC and 70,000 shares directly.

What was the price per share for the acquired RPRX shares?

The acquisition price was $0, reflecting settlement of Equity Performance Awards under Rule 16b-3.

Was this transaction under a 10b5-1 plan?

The form includes a checkbox to indicate 10b5-1 plans; the excerpt does not show it as selected.

What is the nature of the indirect ownership reported?

Indirect ownership of 658,510 shares is held by SCH Investment Partners LLC.